ArticleFrontiers in cell and developmental biology2025
Enhancing preoperative HER2 status classification of invasive breast cancers using machine learning models based on clinicopathological and MRI features: a multicenter study.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multiparametric MRI and artificial intelligence for non-invasive HER2 assessment in breast cancer: a comprehensive review.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale and Objectives: The human epidermal growth factor receptor 2 (HER2) gene status is crucial for determining treatment efficacy. This study assessed preoperative HER2 classification in breast cancer using machine learning based on clinicopathological and MRI characteristics. Materials and Methods: This retrospective study involved 1,015 patients (1,030 lesions) across two centers. Patients were divided into training, internal validation, and external validation sets. Nomograms were developed using clinicopathological and MRI features. Predictive models were constructed using decision trees (DT), support vector machines (SVM), k-nearest neighbors (k-NN), artificial neural networks (ANN), and multivariable logistic regression (LR). Model performance was evaluated using receiver operating characteristic curves, decision curve analysis, and calibration curves. Model interpretability was achieved by developing nomograms and employing SHAP (SHapley Additive exPlanations) analysis. Results: Key variables for distinguishing HER2-positive from HER2-negative cases included regional N category, estrogen receptor, PR (progesterone receptor) status, Ki-67 status, lesion number, distribution quadrant, and accompanying signs. The SVM model achieved the highest AUC of 0.86 (95% confidence interval (CI): 0.81-0.90) in the training set, while the ANN model had an AUC of 0.77 (95% CI: 0.67-0.86) in the internal validation set. In the external validation set, the LR model achieved the highest AUC of 0.66 (95% CI: 0.56-0.76), although the overall performance was modest. For HER2-low versus HER2-zero differentiation, Ki-67 status, lesion number, distribution quadrant, mass shape, early enhancement rate, and ADC (apparent diffusion coefficient) were significant. The SVM model attained the highest AUC of 0.87 (95% CI: 0.83-0.91) in the training set, while the LR model demonstrated superior generalizability, yielding the highest AUCs in both the internal and external validation sets (internal: 0.67, 95% CI: 0.58-0.76; external: 0.74, 95% CI: 0.65-0.83). Radiologists benefited from the nomogram for improved diagnostic accuracy, especially junior radiologists. SHAP analysis revealed that PR status was paramount for HER2-positive classification, whereas mass shape and ADC values were dominant for identifying HER2-low status. Conclusion: Integrating machine learning with clinicopathological and MRI characteristics improves the accuracy of HER2 status classification in breast cancer and enhances diagnostic capabilities for radiologists in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.